Skip to main content

Table 3 Key predictors of clinical malaria episodes due to P. falciparum and P. vivax in 2013

From: Differential impact of malaria control interventions on P. falciparum and P. vivax infections in young Papua New Guinean children

 P. falciparumP. vivax
  Base modelmolFOB adjusted Base modelmolFOB adjusted
 IRIRR (CI95)pIRR (CI95)pIRIRR (CI95)pIRR (CI95)p
Areas of residence
 Ilahita 1–4, 6, 70.05Reference group0.06Reference group
 Balanga & Balif0.030.63 (0.13–3.14)0.5750.56 (0.11–2.81)0.4850.061.15 (0.32–4.06)0.8331.08 (0.30–3.91)0.909
 Kamanokor & Ilahita 50.254.30 (1.59–11.6)0.0043.96 (1.46–10.8)0.0070.528.01 (3.23–19.9)< 0.0013.86 (1.44–10.3)0.007
 Sunuhu 1&20.508.15 (3.40–19.6)< 0.0016.48 (2.65–15.8)< 0.0010.333.71 (1.53–8.99)0.0042.00 (0.77–5.17)0.152
  p < 0.0001a p < 0.0001a  p < 0.0001a p < 0.0234a 
Age 1.38 (1.10–1.73)0.0061.30 (1.03–1.64)0.026     
Haemoglobin 0.52 (0.35–0.77)0.0010.61 (0.40–0.92)0.017 0.31 (0.19–0.48)< 0.0010.38 (0.24–0.59)< 0.001
FOBb   1.10 (1.02–1.18)0.008   1.17 (1.09–1.25)< 0.001
  1. Multivariate negative binomial regression model-based estimates predicting risk of clinical P. falciparum and P. vivax. Backward selection approach was used to derive significant associations. Base models included all variables except molFOB. Incidence is based on aggregated clinical data for entire 10-month study period thus precluding analysis of recent antimalarial treatment as a covariate. Bednet use was not analysed due to non-converge of data when included into models. aOverall significance level for the variable estimated using wald chi-square test; molFOB: molecular force of blood-stage infections; bmolFOB was included as a rate; IR: Incidence rate; IRR: Incidence rate ratio. CI95 95% confidence interval; p p value